
Develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
UK Senior Director Market Access
London, United Kingdom | full time | Job ID: 11308
About the Role:
As the UK Senior Market Access Director, you will be at the forefront of BioNTech’s efforts to bring transformative oncology innovations to patients in the UK. Reporting directly to the UK Country Lead and collaborating with global and local teams, you will establish and lead a UK market access function that supports BioNTech’s transition to a commercial-stage oncology powerhouse. Your work will play a vital role in navigating the NHS ecosystem, ensuring our innovations reach patients while their value is recognized and realized.
This is a unique opportunity for a hands-on leader with a pioneer mentality to build a new function within our UK affiliate. You will drive strategy and execution across market access, pricing, policy, and public affairs, contributing significantly to our mission of improving patient outcomes through cutting-edge immunotherapies.
Your Contribution:
-
Lead, plan, and execute market access and pricing strategies for BioNTech’s oncology portfolio in the UK, including NICE and SMC appraisals.
-
Build and develop the UK market access team as the first in-market team member while fostering a culture of launch excellence.
-
Develop integrated market access plans tailored to UK-specific requirements, ensuring alignment with global strategies.
-
Drive innovative solutions to overcome pricing and reimbursement barriers, including managed access agreements (MAAs) and value-based arrangements.
-
Provide strategic input at senior leadership discussions and contribute to the overall business strategy for the UK affiliate.
-
Engage with key stakeholders such as policymakers, budget-holders, health authorities (e.g., NHSE, DHSC, NICE), and industry associations to position BioNTech as a trusted partner within the NHS ecosystem.
A Good Match:
-
Advanced university degree in natural sciences, business administration, health economics, or related fields; strong scientific literacy in oncology is essential.
-
10+ years of leadership experience within market access or health economics functions in the pharmaceutical/biotech industry; 5+ years in oncology with significant UK market expertise.
-
Proven track record of leading successful NICE and SMC appraisals for oncology products, including experience with novel-novel combinations; adept at tailoring strategies for diverse access challenges.
-
Strong HEOR knowledge and experience, with a particular focus on UK HEOR strategies and deliverables.
-
Strong knowledge of the UK healthcare landscape, including NICE HTA processes, NHS England commercial medicines reimbursement pathways, and VPAG frameworks.
-
Experience in commercial areas such as marketing and sales is desirable.
-
Demonstrated ability to build teams from scratch in fast-paced environments.
-
Strategic thinking and problem-solving, including a willingness to innovate and challenge the status quo; and an ability to combine this with hands-on execution.
-
Excellent collaboration skills with experience managing cross-functional projects.
Your Benefits:
BioNTech is committed to the wellbeing of our team members and offers a variety of benefits in support of our diverse employee base. We offer competitive remuneration packages which is determined by the specific role, location of employment and also the selected candidate’s qualifications and experience.
Note: The availability, eligibility and design of the listed benefits may vary depending on the location. The final requirements for the individual use of our benefits are based on the company's internal policies and applicable law.
How to apply:
Apply now by sending us your application documents including Curriculum Vitae, copy of ID, copies of degree certificates and professional certificates, motivation letter as well as your contact details via our online form.
Please note:
Only applications sent via our online form shall be considered. By submitting your application, you acknowledge that a background check will be conducted as part of the recruitment process in accordance with applicable laws and regulations. If you are considered for the position, BioNTech will conduct the background check through our service provider ‘Hire Right’. You will be informed accordingly by your BioNTech-Recruiter.
We are looking forward receiving your application.
閲覧数
1
応募クリック
0
Mock Apply
0
スクラップ
0
類似の求人

Retail Associate Manager
T-Mobile · Dearborn, Michigan

Agency and Partner Lead, Large Customer Sales

Digital Sales Lead
ABB · Buenos Aires, Capital Federal, Argentina

Territory Manager Market Support - Spokane, WA
US Foods · SPOKANE, Washington, United States of America

Specialty Sales Manager
Intuitive Surgical · Stockholm
BioNTechについて

BioNTech
PublicBioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
1,001-5,000
従業員数
Mainz that develops immunotherapies
本社所在地
$21.7B
企業価値
レビュー
10件のレビュー
4.0
10件のレビュー
ワークライフバランス
2.8
報酬
3.7
企業文化
4.2
キャリア
3.5
経営陣
3.3
78%
知人への推奨率
良い点
Innovative and cutting-edge technology projects
Supportive and collaborative team environment
Meaningful and impactful work with strong mission
改善点
Long working hours and high workload
Fast-paced environment can be stressful
High pressure and expectations
給与レンジ
38件のデータ
L2
L6
Mid/L4
Intern
L3
L4
L5
L2 · Data Scientist L2
0件のレポート
$53,767
年収総額
基本給
$21,507
ストック
$26,884
ボーナス
$5,377
$37,637
$69,897
面接レビュー
レビュー1件
難易度
3.0
/ 5
期間
14-28週間
面接プロセス
1
Application Review
2
HR Screen
3
Hiring Manager Interview
4
Panel Interview
5
Final Interview
6
Offer
よくある質問
Behavioral/STAR
Technical Knowledge
Past Experience
Culture Fit
Problem Solving
最新情報
New Drugs for Pancreatic Cancer Show Remarkable Promise for Deadly Disease - WSJ
WSJ
News
·
2w ago
Investigational Pancreatic Cancer Vaccine Shows Lasting Results in Early Trial, Supporting Continued Testing - Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
News
·
2w ago
BioNTech’s BNT323 Achieves Strong Phase 2 Response Rates in Endometrial Cancer - Oncodaily
Oncodaily
News
·
2w ago
BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story - simplywall.st
simplywall.st
News
·
3w ago